{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T20:34:41Z","timestamp":1794170081667,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V115C-095"],"award-info":[{"award-number":["V115C-095"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114B-015"],"award-info":[{"award-number":["V114B-015"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V115B-008"],"award-info":[{"award-number":["V115B-008"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114C-039"],"award-info":[{"award-number":["V114C-039"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-075 -057 -MY3"],"award-info":[{"award-number":["113-2314-B-075 -057 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["110-2314-B-075-016 MY3"],"award-info":[{"award-number":["110-2314-B-075-016 MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.tjog.2025.12.001","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:47:33Z","timestamp":1769629653000},"page":"22-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Chemoresistance in ovarian cancer (I)"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-8541","authenticated-orcid":false,"given":"Peng-Hui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahmana Askandar","family":"Tjokroprawiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tjog.2024.05.006","article-title":"Evolving treatment paradigms for platinum-resistant ovarian cancer: an update narrative review","volume":"63","author":"Lin","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib2","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00280-017-3468-5","article-title":"Combination chemotherapy with irinotecan and gemcitabine for taxane\/platinumresistant\/refractory ovarian and primary peritoneal cancer: a multicenter phase I\/II trial (GOGO-Ov 6)","volume":"80","author":"Yoshino","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.tjog.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.3802\/jgo.2021.32.e8","article-title":"Tailoreddose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory\/resistant ovarian or primary peritoneal cancer: a phase II trial","volume":"32","author":"Tate","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2020.07.028","article-title":"Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib9","article-title":"Niraparib, dostarlimab, and Bevacizumab as combination therapy in pretreated, advanced platinum-resistant ovarian cancer: findings from cohort A of the OPAL phase II trial","volume":"8","author":"Liu","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Gynecologic Oncology group partners and the European network of gynaecological oncological trial groups. Mirvetuximab soravtansine in FR\u03b1-Positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2025.12.001_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.tjog.2025.09.003","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (III): understanding of ADC","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.tjog.2024.09.005","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.tjog.2025.09.018","article-title":"Targeted biomarkers of antibody-drug conjugates (ADCs)","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib14","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","article-title":"Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study","volume":"28","author":"Moore","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjog.2025.12.001_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum refractory recurrent ovarian cancer: a double-blind, randomised, placebo controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2025.12.001_bib17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s11523-024-01102-8","article-title":"Adavosertib in combination with olaparib in patients with refractory solid tumors: an Open-Label, Dose-Finding, and dose-expansion phase Ib trial","volume":"19","author":"Hamilton","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104706","article-title":"Strategies to overcome chemoresistance in epithelial ovarian cancer: navigating beyond challenges","volume":"210","author":"Nguyen","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.tjog.2025.12.001_bib19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/ijms26062545","article-title":"Precision medicine in high-grade serous ovarian cancer: targeted therapies and the challenge of chemoresistance","volume":"26","author":"Polaj\u017eer","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tjog.2025.12.001_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189261","article-title":"Combating chemoresistance: current approaches & nanocarrier mediated targeted delivery","volume":"1880","author":"Shaw","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.tjog.2025.12.001_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118719","article-title":"DNA repair pathways in ovarian cancer: implications for therapy and resistance","volume":"193","author":"Miras","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.tjog.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.tjog.2024.07.013","article-title":"Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tjog.2024.11.006","article-title":"Current genetic test for ovarian cancer","volume":"64","author":"Yang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/JCMA.0000000000001253","article-title":"Is C3c structure useful as biomarkers for epithelial ovarian cancer?","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.12.001_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/JCMA.0000000000001317","article-title":"Programmed death-ligand 1 (PD-L1) upregulation is associated with poor prognosis in patients with epithelial ovarian cancer","volume":"89","author":"Liu","year":"2026","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.12.001_bib26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.tjog.2025.09.019","article-title":"Completeness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tjog.2024.11.003","article-title":"Primary cytoreductive surgery for advanced epithelial ovarian cancer patients is still popular in gynecologic oncologists in Korea and Taiwan, particularly apparent in Taiwan","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.tjog.2024.09.002","article-title":"Neoadjuvant chemotherapy is associated with worse prognosis in patients with advanced-stage epithelial ovarian cancer: is it real?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2024.100714","article-title":"Mitochondrial dysfunction route as a possible biomarker and therapy target for human cancer","volume":"48","author":"Al-Faze","year":"2025","journal-title":"Biomed J"},{"key":"10.1016\/j.tjog.2025.12.001_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123966","article-title":"Autophagy regulation in ovarian cancer chemoresistance: molecular mechanisms and emerging frontiers","volume":"380","author":"Yang","year":"2025","journal-title":"Life Sci"},{"key":"10.1016\/j.tjog.2025.12.001_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189451","article-title":"Functional dichotomy of autophagy signaling in tumor microenvironment driving hallmarks in oral cancer","volume":"1880","author":"Patra","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.tjog.2025.12.001_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101170","article-title":"Autophagy in cancer development, immune evasion, and drug resistance","volume":"78","author":"Niu","year":"2025","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.tjog.2025.12.001_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166400","article-title":"Role and regulation of autophagy in cancer","volume":"1868","author":"Rakesh","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.tjog.2025.12.001_bib34","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.3390\/biomedicines13112820","article-title":"Epigenetics in ovarian cancer: a review of Current knowledge and future perspectives","volume":"13","author":"Dedes","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.tjog.2025.12.001_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/JCMA.0000000000001272","article-title":"The trend of utilizing de-escalation of surgical extent for treating early-stage cervical cancer patients","volume":"88","author":"Yang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.12.001_bib36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tjog.2024.07.014","article-title":"Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer","volume":"63","author":"Chang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib37","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JCMA.0000000000001157","article-title":"Neoadjuvant therapy and locally advanced cancer diseases","volume":"87","author":"Wang","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.12.001_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ijgo.15609","article-title":"Bevacizumab is associated with a higher gastrointestinal\/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy","volume":"167","author":"Yang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.12.001_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JCMA.0000000000001069","article-title":"Minimally invasive approach is preferred for clinical stage 1 endometrioid-type endometrial cancer","volume":"87","author":"Wang","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.12.001_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tjog.2025.10.001","article-title":"The role of secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treating recurrent ovarian cancer","volume":"65","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JCMA.0000000000001077","article-title":"CA 125 for surgico-pathological stage 1 endometrial cancer","volume":"87","author":"Wang","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.12.001_bib42","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.hoc.2025.04.018","article-title":"Surgery for recurrent ovarian cancer","volume":"39","author":"Levy","year":"2025","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.tjog.2025.12.001_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tjog.2023.11.005","article-title":"Front-line chemoimmunotherapy for treating epithelial ovarian cancer: part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib44","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.tjog.2023.09.017","article-title":"Front-line chemo-immunotherapy for treating epithelial ovarian cancer: part I CA125 and anti-CA125","volume":"62","author":"Yang","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.tjog.2025.12.001_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijgo.70282","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2025 update","volume":"171","author":"Renz","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 1","key":"10.1016\/j.tjog.2025.12.001_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijgo.70033","article-title":"Worldwide barriers of optimal surgical care provision in advanced ovarian cancer","volume":"171","author":"Varghese","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.12.001_bib47","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ijgo.15263","article-title":"Nomograms for predicting overall survival and cancer-specific survival of endometrioid ovarian carcinoma: a retrospective cohort study from the SEER database","volume":"165","author":"Wang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.12.001_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ijgo.15261","article-title":"Prognostic factors and novel nomograms for overall survival and cancer specific survival of malignant ovarian cancer patients with bone metastasis: a SEER-based study","volume":"165","author":"Luo","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.12.001_bib49","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.tjog.2024.05.022","article-title":"A nomogram to predict platinum-sensitivity and survival outcome in women with advanced epithelial ovarian cancer","volume":"63","author":"Yeh","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib50","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.tjog.2025.05.015","article-title":"KELIM score and BRCA status are unreliable to predict the completeness of cytoreduction during interval debulking surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancers","volume":"64","author":"Fan","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib51","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jfma.2024.08.014","article-title":"Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: a single-center retrospective cohort study","volume":"124","author":"Wu","year":"2025","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.tjog.2025.12.001_bib52","article-title":"Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis","volume":"36","author":"Kim","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2025.12.001_bib53","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1136\/ijgc-2024-005876","article-title":"Role of secondary cytoreduction in relapsed ovarian cancer","volume":"34","author":"Gouveia","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2025.12.001_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110424","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: a systematic review and meta-analysis of randomized control trials","volume":"51","author":"Guerra","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jso.28166","article-title":"Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of epithelial ovarian cancer: a GRADE approach for evidence evaluation and recommendation","volume":"132","author":"Brennan","year":"2025","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib56","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.tjog.2024.05.020","article-title":"Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: a systematic review and meta-analysis","volume":"63","author":"Adrianto","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.12.001_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115522","article-title":"Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer","volume":"224","author":"Porter","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2025.12.001_bib59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3892\/or.2025.8901","article-title":"Monotherapy and combination therapy using antibody-drug conjugates for platinum-resistant ovarian cancer","volume":"53","author":"Shen","year":"2025","journal-title":"Oncol Rep"},{"key":"10.1016\/j.tjog.2025.12.001_bib60","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer","volume":"200","author":"Matulonis","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2025.12.001_bib61","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.tjog.2025.04.013","article-title":"HER2 mutation profiling in mucinous ovarian carcinoma: inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach","volume":"64","author":"Shen","year":"2025","journal-title":"Taiwan J Obstet Gynecol"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925003390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925003390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:15:44Z","timestamp":1778580944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455925003390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1028455925003390"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2025.12.001","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoresistance in ovarian cancer (I)","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}